JP2000506725A - 細胞増殖の阻害 - Google Patents

細胞増殖の阻害

Info

Publication number
JP2000506725A
JP2000506725A JP9531259A JP53125997A JP2000506725A JP 2000506725 A JP2000506725 A JP 2000506725A JP 9531259 A JP9531259 A JP 9531259A JP 53125997 A JP53125997 A JP 53125997A JP 2000506725 A JP2000506725 A JP 2000506725A
Authority
JP
Japan
Prior art keywords
egr
expression
mrna
cells
ribozyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP9531259A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000506725A5 (enExample
Inventor
カーチギアン，レボン，マイケル
Original Assignee
ユニサーチ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニサーチ リミテッド filed Critical ユニサーチ リミテッド
Publication of JP2000506725A publication Critical patent/JP2000506725A/ja
Publication of JP2000506725A5 publication Critical patent/JP2000506725A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
JP9531259A 1996-03-07 1997-03-07 細胞増殖の阻害 Ceased JP2000506725A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU8554 1984-12-13
AUPN8554A AUPN855496A0 (en) 1996-03-07 1996-03-07 Prevention of proliferation of vascular cells
PCT/AU1997/000140 WO1997032979A1 (en) 1996-03-07 1997-03-07 Inhibition of proliferation of cells

Publications (2)

Publication Number Publication Date
JP2000506725A true JP2000506725A (ja) 2000-06-06
JP2000506725A5 JP2000506725A5 (enExample) 2004-12-02

Family

ID=3792866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9531259A Ceased JP2000506725A (ja) 1996-03-07 1997-03-07 細胞増殖の阻害

Country Status (7)

Country Link
US (1) US6200960B1 (enExample)
EP (1) EP0934404A4 (enExample)
JP (1) JP2000506725A (enExample)
AU (1) AUPN855496A0 (enExample)
CA (1) CA2248350A1 (enExample)
WO (1) WO1997032979A1 (enExample)
ZA (1) ZA972000B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003060516A1 (en) * 2002-01-10 2003-07-24 Takeda Chemical Industries, Ltd. Screening method

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099438A1 (en) 1998-04-15 2002-07-25 Furst Joseph G. Irradiated stent coating
US20030040790A1 (en) * 1998-04-15 2003-02-27 Furst Joseph G. Stent coating
US6979728B2 (en) * 1998-05-04 2005-12-27 Baylor College Of Medicine Articles of manufacture and methods for array based analysis of biological molecules
DK1083934T3 (da) * 1998-06-02 2003-12-01 Glaxo Group Ltd Genterapifremgangsmåder
US7967855B2 (en) * 1998-07-27 2011-06-28 Icon Interventional Systems, Inc. Coated medical device
US8070796B2 (en) 1998-07-27 2011-12-06 Icon Interventional Systems, Inc. Thrombosis inhibiting graft
US6008048A (en) * 1998-12-04 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of EGR-1 expression
AUPP810399A0 (en) 1999-01-11 1999-02-04 Unisearch Limited Catalytic molecules
AUPQ367699A0 (en) * 1999-10-26 1999-11-18 Unisearch Limited Treatment of cancer
GB9928430D0 (en) * 1999-12-01 2000-01-26 Glaxo Group Ltd Screening
WO2001068158A1 (en) * 2000-03-15 2001-09-20 Orbus Medical Technologies Inc. Coating that promotes endothelial cell adherence
US8740973B2 (en) * 2001-10-26 2014-06-03 Icon Medical Corp. Polymer biodegradable medical device
US6979296B2 (en) * 2002-04-03 2005-12-27 Sbm Biologics, Inc. Methods for ultrasonic imaging and treating diseased tissues
EP1518207A1 (en) * 2002-07-03 2005-03-30 Quelis ID Systems, Inc. Wire positioning and mechanical attachment for a radio-frequency identification device
US8016881B2 (en) * 2002-07-31 2011-09-13 Icon Interventional Systems, Inc. Sutures and surgical staples for anastamoses, wound closures, and surgical closures
DE10355511A1 (de) * 2003-11-24 2005-06-09 Biotronik Gmbh & Co. Kg Endovasculäres Implantat mit einer aktiven Beschichtung
US7211108B2 (en) * 2004-01-23 2007-05-01 Icon Medical Corp. Vascular grafts with amphiphilic block copolymer coatings
US7968762B2 (en) * 2004-07-13 2011-06-28 Van Andel Research Institute Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
US9107899B2 (en) 2005-03-03 2015-08-18 Icon Medical Corporation Metal alloys for medical devices
US20060201601A1 (en) * 2005-03-03 2006-09-14 Icon Interventional Systems, Inc. Flexible markers
US7540995B2 (en) 2005-03-03 2009-06-02 Icon Medical Corp. Process for forming an improved metal alloy stent
US20060264914A1 (en) * 2005-03-03 2006-11-23 Icon Medical Corp. Metal alloys for medical devices
WO2006110197A2 (en) * 2005-03-03 2006-10-19 Icon Medical Corp. Polymer biodegradable medical device
WO2006096251A2 (en) * 2005-03-03 2006-09-14 Icon Medical Corp. Improved metal alloys for medical device
US8323333B2 (en) * 2005-03-03 2012-12-04 Icon Medical Corp. Fragile structure protective coating
WO2007118157A1 (en) * 2006-04-05 2007-10-18 Joslin Diabetes Center, Inc. Enhancing stem cell mobilization
WO2008008291A2 (en) * 2006-07-13 2008-01-17 Icon Medical Corp. Stent
EP2350264A4 (en) 2008-11-06 2012-08-29 Univ Johns Hopkins TREATMENT OF CHRONIC INFLAMMATION OF THE RESPIRATORY TRACT
US8398916B2 (en) 2010-03-04 2013-03-19 Icon Medical Corp. Method for forming a tubular medical device
BR112016030273A8 (pt) 2014-06-24 2021-05-18 Icon Medical Corp dispositivo médico e método para formar o referido dispositivo
US11766506B2 (en) 2016-03-04 2023-09-26 Mirus Llc Stent device for spinal fusion

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206152A (en) * 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003060516A1 (en) * 2002-01-10 2003-07-24 Takeda Chemical Industries, Ltd. Screening method

Also Published As

Publication number Publication date
WO1997032979A1 (en) 1997-09-12
AUPN855496A0 (en) 1996-04-04
CA2248350A1 (en) 1997-09-12
ZA972000B (en) 1997-10-24
EP0934404A1 (en) 1999-08-11
US6200960B1 (en) 2001-03-13
EP0934404A4 (en) 2002-08-07

Similar Documents

Publication Publication Date Title
US6200960B1 (en) Inhibition of proliferation of cells
Pandey et al. Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1
JP3316216B2 (ja) 安定化外部ガイド配列
US6566127B1 (en) Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
KR100252547B1 (ko) 폴리-또는 올리고누클레오티드의 세포로의 표적화된 전달
KR100316205B1 (ko) 평활근세포의증식을조절하기위한c-myc의안티센스억제
CA2547780C (en) Antisense compounds targeted to connexins and methods of use thereof
JP6837963B2 (ja) Ｍｉｒ−２９模倣物およびその使用
CN105658797A (zh) 用于调节rna的组合物和方法
JPH10500309A (ja) リボザイムを用いて再狭窄および癌を治療するための方法および組成物
JPH09507381A (ja) 血管平滑筋細胞の増殖の阻害
JPH09503651A (ja) 血管内皮細胞増殖因子発現のアンチセンスオリゴヌクレオチド阻害
HU215187B (hu) Eljárás az RNS funkcióját gátló genetikai egységek előállítására, és eljárás sejtekbe való bevitelükre
KR20150004906A (ko) 항-코넥신 화합물 및 그의 용도
CA2795281A1 (en) Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
JP2013511964A (ja) ｍｉＲＮＡ−１００を含む医薬組成物ならびに血管増殖および内皮炎症を調節するためのその使用
JP2005525802A (ja) 血管治療
EP1206527A1 (en) Treatment of inflammatory or malignant disease using dnazymes
KR100808965B1 (ko) 촉매성 분자
US20040220131A1 (en) Method for treatment of cancerous angiogenic disorders
AU707943B2 (en) Inhibition of proliferation of cells
JP2003512442A (ja) 癌の治療法
JP2002509721A (ja) 脈管形成応答に関与する分子に関連する疾病または状態の治療のための方法および試薬
US20040072768A1 (en) Inhibition of proliferation of cells
EP1197553A1 (en) Antisense nucleic acid against alphaV integrin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060921

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20061106

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20070216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070320